Movement Alert｜WUXI BIO Falls 4.4% in Regular Trading, Profit-Taking Extends After Strong Interim Results

Market Focus09:40

On August 31, WUXI BIO fell 4.4% in regular trading, trading at HK$49.82/share, with turnover of HK$260 million. The decline reflects continued profit-taking pressure following the company's strong interim results released on August 25.

The company reported H1 revenue of RMB 11.787 billion, up 18.4% year-over-year, with adjusted net profit attributable to shareholders surging 38.4%. Management also raised full-year revenue growth guidance to 15%-18%. Multiple investment banks subsequently upgraded their target prices, with CICC and CMB International both raising targets to HK$60, Daiwa to HK$59, and Morgan Stanley to HK$57.

However, the earnings beat and upgraded outlook had been largely priced in during the prior rally. A sector-wide pullback began on August 27, and selling pressure from profit-taking has persisted. Peers including WUXI APPTEC and WUXI XDC also declined, with the broader Life Sciences Tools & Services sector trending weak. TIGERMED was the sole outlier, rising 11.01%, while INSILICO fell 3.71%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1131736725?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-31 09:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1131736725","market":"us","top_or_hot":-1,"title":"Movement Alert｜WUXI BIO Falls 4.4% in Regular Trading, Profit-Taking Extends After Strong Interim Results","media":"Market Focus","content":"<p><p>On August 31, WUXI BIO fell 4.4% in regular trading, trading at HK$49.82/share, with turnover of HK$260 million. The decline reflects continued profit-taking pressure following the company's strong interim results released on August 25.</p><p>The company reported H1 revenue of RMB 11.787 billion, up 18.4% year-over-year, with adjusted net profit attributable to shareholders surging 38.4%. Management also raised full-year revenue growth guidance to 15%-18%. Multiple investment banks subsequently upgraded their target prices, with CICC and CMB International both raising targets to HK$60, Daiwa to HK$59, and Morgan Stanley to HK$57.</p><p>However, the earnings beat and upgraded outlook had been largely priced in during the prior rally. A sector-wide pullback began on August 27, and selling pressure from profit-taking has persisted. Peers including WUXI APPTEC and WUXI XDC also declined, with the broader Life Sciences Tools & Services sector trending weak. TIGERMED was the sole outlier, rising 11.01%, while INSILICO fell 3.71%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜WUXI BIO Falls 4.4% in Regular Trading, Profit-Taking Extends After Strong Interim Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜WUXI BIO Falls 4.4% in Regular Trading, Profit-Taking Extends After Strong Interim Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-31 09:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 31, WUXI BIO fell 4.4% in regular trading, trading at HK$49.82/share, with turnover of HK$260 million. The decline reflects continued profit-taking pressure following the company's strong interim results released on August 25.</p><p>The company reported H1 revenue of RMB 11.787 billion, up 18.4% year-over-year, with adjusted net profit attributable to shareholders surging 38.4%. Management also raised full-year revenue growth guidance to 15%-18%. Multiple investment banks subsequently upgraded their target prices, with CICC and CMB International both raising targets to HK$60, Daiwa to HK$59, and Morgan Stanley to HK$57.</p><p>However, the earnings beat and upgraded outlook had been largely priced in during the prior rally. A sector-wide pullback began on August 27, and selling pressure from profit-taking has persisted. Peers including WUXI APPTEC and WUXI XDC also declined, with the broader Life Sciences Tools & Services sector trending weak. TIGERMED was the sole outlier, rising 11.01%, while INSILICO fell 3.71%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02269","symbol_name":"药明生物","start_time":0,"source_url":"","article_id":"1131736725","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1131736725","pubTimestamp":1788140455,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 31, WUXI BIO fell 4.4% in regular trading, trading at HK$49.82/share, with turnover of HK$260 million. The decline reflects continued profit-taking pressure following the company's strong...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02269":"药明生物"},"translate_title":"走势警报|药明生物常规交易下跌4.4%，中期业绩强劲后获利了结延长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02269":1},"content_text":"On August 31, WUXI BIO fell 4.4% in regular trading, trading at HK$49.82/share, with turnover of HK$260 million. The decline reflects continued profit-taking pressure following the company's strong interim results released on August 25.The company reported H1 revenue of RMB 11.787 billion, up 18.4% year-over-year, with adjusted net profit attributable to shareholders surging 38.4%. Management also raised full-year revenue growth guidance to 15%-18%. Multiple investment banks subsequently upgraded their target prices, with CICC and CMB International both raising targets to HK$60, Daiwa to HK$59, and Morgan Stanley to HK$57.However, the earnings beat and upgraded outlook had been largely priced in during the prior rally. A sector-wide pullback began on August 27, and selling pressure from profit-taking has persisted. Peers including WUXI APPTEC and WUXI XDC also declined, with the broader Life Sciences Tools & Services sector trending weak. TIGERMED was the sole outlier, rising 11.01%, while INSILICO fell 3.71%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.48.0","shortVersion":"4.48.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1131736725","isCrawlerRequest":true}